Department of Cardiovascular Surgery, Teikyo University, Tokyo, Japan.
Department of Cardiovascular Surgery, Teikyo University, Tokyo, Japan.
Transplant Proc. 2024 Apr;56(3):692-700. doi: 10.1016/j.transproceed.2024.01.015. Epub 2024 Feb 15.
We demonstrated that an agonistic anti-B and T lymphocyte attenuator antibody (3C10) prolonged cardiac survival by inducing regulatory T cells (Treg). However, the mechanisms of immune tolerance in the recipients remained unclear. In this study, we investigated the graft-protective and intercellular immunomodulatory effects of adoptive transfer (AT) of 3C10-induced Tregs in a murine cardiac allograft transplant model.
Thirty days after transplantation of a C57BL/6 heart into the primary 3C10-treated CBA recipients, splenic CD4CD25 cells from these recipients (3C10/AT group) or naïve CBA mice (no-treatment group) were adoptively transferred into secondary CBA recipients with a C57BL/6 heart. To confirm the requirement for 3C10-induced Tregs, we administered an anti-interleukin-2 receptor alpha antibody (PC-61) to secondary CBA recipients. Additionally, histologic and fluorescent staining, cell proliferation analysis, flow cytometry, and donor-specific antibody (DSA) measurements were performed.
3C10/AT-treated CBA recipients resulted in significantly prolonged allograft survival (median survival time [MST], >50 days). Allografts displayed prolonged function with preservation of vessel structure by maintaining high numbers of splenic CD4CD25Foxp3 Treg and intramyocardial CD4Foxp3 cells. DSA levels were suppressed in 3C10/AT-treated CBA recipients. Moreover, PC-61 administration resulted in a shorter MSTs of cardiac allograft survivals, a detrimental increase in DSA production, and enhanced expression of programmed cell death (PD)-1.
AT of 3C10-induced Tregs may be a promising graft-protective strategy to prolong allograft survival and suppress DSA production, driven by the promotion of splenic and graft-infiltrating Tregs and collaboration with PD-1 T cells and Treg.
我们已经证实,激动性抗 B 和 T 淋巴细胞衰减子抗体(3C10)通过诱导调节性 T 细胞(Treg)来延长心脏的存活期。然而,受者的免疫耐受机制尚不清楚。在这项研究中,我们在小鼠心脏移植模型中研究了 3C10 诱导的 Treg 的过继转移(AT)对移植物的保护和细胞间免疫调节作用。
在原发性 3C10 处理的 CBA 受者接受 C57BL/6 心脏移植 30 天后,从这些受者的脾 CD4CD25 细胞(3C10/AT 组)或幼稚的 CBA 小鼠(未治疗组)中过继转移到接受 C57BL/6 心脏的继发性 CBA 受者中。为了确认 3C10 诱导的 Treg 的需求,我们给次级 CBA 受者施用抗白细胞介素-2 受体 α 抗体(PC-61)。此外,进行了组织学和荧光染色、细胞增殖分析、流式细胞术和供体特异性抗体(DSA)测量。
3C10/AT 治疗的 CBA 受者导致移植物存活期显著延长(中位存活时间 [MST],>50 天)。同种异体移植物功能延长,血管结构得以维持,脾 CD4CD25Foxp3 Treg 和心肌内 CD4Foxp3 细胞数量保持较高水平。3C10/AT 治疗的 CBA 受者中的 DSA 水平受到抑制。此外,PC-61 的给予导致心脏移植物存活的 MST 缩短,DSA 产生的有害增加,以及程序性细胞死亡(PD)-1 的表达增强。
3C10 诱导的 Treg 的 AT 可能是一种有前途的移植物保护策略,可延长移植物存活期并抑制 DSA 的产生,这是通过促进脾和移植物浸润的 Treg 以及与 PD-1 T 细胞和 Treg 的协作来实现的。